HIV / AIDS
CROI 2013: Does Hormonal Contraception Raise the Risk of HIV Infection? [VIDEO]
- Details
- Category: HIV Prevention
- Published on Monday, 11 March 2013 00:00
Use of hormonal contraception such as Depo-Provera does not appear to increase the likelihood of women becoming infected with HIV, nor was it associated with greater HIV shedding among women on antiretroviral therapy (ART), which could increase transmission risk, according to 2 studies presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
Some prior research has suggested that use of hormonal contraceptives like the injectable depo-medroxyprogesterone acetate (DMPA or Dep-Provera) may be associated with increased risk of HIV acquisition or transmission, but data have been inconclusive and some studies looked at untreated people rather than those on ART.
Angela Crook from the MRC Clinical Trials Unit in London evaluated the association between hormonal contraception use and risk of HIV among women participating in a large Microbicides Development Programme trial.
Summer Day from the University of Washington in Seattle looked at the converse question: whether using hormonal contraception makes it more likely that HIV positive women on ART will transmit the virus to their sexual partners.
Both studies found that the answer appears to be no. Neither found a link between hormonal contraceptive use and HIV acquisition or transmission, respectively. According to Day, these findings do not support efforts to restrict women with HIV from using hormonal methods, but rather suggest an additional potential benefit of early ART.
[Angela Crook and Summer Day speak at CROI HIV prevention press conference, Atlanta, March 5, 2013]
3/11/13
Reference
A Crook, H Rees, G Ramjee, et al. Hormonal Contraception and Risk of HIV: An Analysis of Data from the Microbicides Development Programme Trial. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 28.
S Day, S Graham, L Masese, et al. Is Depot Medroxyprogesterone Acetate Likely to Increase Infectivity in HIV-1+ Women Receiving ART? 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, March 3-6, 2013. Abstract 29.
CROI 2013: Black Gay Men Have Higher HIV Risk Despite Fewer Partners
- Details
- Category: HIV Prevention
- Published on Monday, 11 March 2013 00:00
An analysis of 4 studies of sexual risk and HIV infection in U.S. gay men, presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta, has found a 22% higher risk of HIV infection per sexual contact among black gay men that is not explained by other factors such as number of sexual partners, injecting drug use, or age.
CROI 2013: New Antiretroviral Agents: Cenicriviroc [VIDEO]
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
Tobira's cenicriviroc, a dual CCR5 and CCR2 receptor blocker with both antiviral and anti-inflammatory action, appears effective and better tolerated than some currently approved drugs, according to data presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
March 10 Is National Women and Girls HIV/AIDS Awareness Day
- Details
- Category: Women & HIV
- Published on Sunday, 10 March 2013 00:00
Sunday is National Women and Girls HIV/AIDS Awareness Day (NWGHAAD), an annual opportunity to call attention to the burden of HIV and AIDS among women and girls worldwide.
According to the U.S. Centers for Disease Control and Prevention (CDC), women and adolescent girls (aged 13 and older) accounted for 21% of the nearly 50,000 new HIV diagnoses in the U.S. in 2011. The CDC estimates that just over 279,000 women and girls were living with HIV at the end of 2009 -- including 15% who are not aware they are infected.
CROI 2013: New Pro-drug Tenofovir Alafenamide Appears Equally Effective but Better Tolerated
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
Tenofovir alafenamide fumarate, or TAF (formerly GS-7340), a new pro-drug of the widely used NRTI tenofovir, reaches cells harboring HIV more easily than the older disoproxil fumarate (TDF), allowing for similar antiviral efficacy with smaller doses and with less adverse effect on kidneys and bones,researchers reported Tuesday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
CROI 2013: Dolutegravir Helps Highly-resistant Treatment-experienced People on Failing ART
- Details
- Category: HIV Treatment
- Published on Friday, 08 March 2013 00:00
The next-generation integrase inhibitor dolutegravir proved more beneficial than raltegravir (Isentress) for highly treatment-experienced people with resistance to 2 or more antiretroviral drug classes, researchers reported in a poster presented at the20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) this week in Atlanta.
CROI 2013: Can People with Resistant HIV Omit NRTIs When Switching to a New Regimen? [VIDEO]
- Details
- Category: HIV Treatment
- Published on Thursday, 07 March 2013 00:00
Omitting nucleoside reverse transcriptase inhibitors (NRTIs) when switching from a non-suppressive regimen to a new combination with at least 2 active agents can reduce pill burden and side effects without compromising effectiveness, researchers reported yesterday at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
More Articles...
- CROI 2013: HIV Treatment for Children Safe and Highly Effective without Laboratory Monitoring
- CROI 2013: New Tenofovir Alafenamide Looks Easier on Kidneys [VIDEO]
- CROI 2013: Monthly Injectable and Tenofovir Vaginal Ring Protect Monkeys against Infection
- CROI 2013: CCR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-inflammatory Effects
- CROI 2013: MK-1439, a Novel HIV NNRTI, Shows Promise in Early Clinical Trials
Web Design and Development by